Avanza Fonder Ab Neurocrine Biosciences Inc Transaction History
Avanza Fonder Ab
- $3.38 Trillion
- Q2 2025
A detailed history of Avanza Fonder Ab transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Avanza Fonder Ab holds 3,267 shares of NBIX stock, worth $479,007. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,267
Previous 12,474
73.81%
Holding current value
$479,007
Previous $1.35 Billion
69.61%
% of portfolio
0.01%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
657Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.08 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.44 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$816 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$655 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$453 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...